ABCAM Plc Notice of Results (6507O)

TIDMABC

RNS Number : 6507O

ABCAM Plc

10 February 2016

10 February 2016

ABCAM PLC

("Abcam" or "the Company")

Notice of Interim Results

Cambridge UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, expects to announce its interim results for the six month period ended 31 December 2015 on 7 March 2016. A briefing for analysts will be held at 09.30 GMT on 7 March at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD. A live audio webcast and slide presentation of this event will also be available at www.abcamplc.com.

 
                                        + 44 (0) 1223 
Abcam                                    696 000 
Alan Hirzel, Chief Executive Officer 
 Jeff Iliffe, Chief Financial Officer 
 Julia Wilson - Investor Relations 
J.P.Morgan Cazenove - Nominated         + 44 (0) 20 
 Adviser & Corporate Broker              7742 4000 
James Mitford / Alex Bruce 
 
FTI Consulting 
 Ben Atwell / Brett Pollard / Natalie   +44 (0) 20 
 Garland-Collins                         3727 1000 
 

Notes for editors:

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Two-thirds of the world's 750,000 life science researchers use Abcam's affinity binders, reagents, biomarkers and assays and the company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.

By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Abcam's ten offices are located in the world's leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company now employs over 800 people and sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com and www.abcamplc.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORBGGDDRUBBGLG

(END) Dow Jones Newswires

February 10, 2016 05:59 ET (10:59 GMT)